Evidence map›Paper›PMID 35116740›Full record

ArticleTranslational cancer research2019

Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.

Chunyan Xue, Dawei Zhu, Lujun Chen, Yun Xu, Bin Xu, Dachuan Zhang, Jingting Jiang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chunyan Xue *Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Dawei Zhu *Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Lujun ChenDepartment of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Yun XuDepartment of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Bin XuDepartment of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Dachuan ZhangDepartment of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Jingting JiangDepartment of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the present study, we aimed to investigate the expression and prognostic value of co-stimulatory molecules, programmed death ligand-1 (PD-L1) and PD-L2, in ovarian cancer (OC).

methodsImmunohistochemical (IHC) staining was used to assess the expressions of PD-L1 and PD-L2 in 77 cases of OC, and 10 cases of benign ovarian cyst were employed as negative controls. Moreover, χ

resultsPD-L1 and PD-L2 were mainly expressed on membrane and in cytoplasm of OC cells. The high-expression rate of PD-L1 and PD-L2 in OC tissues was 44.16% (34/77) and 22.08% (17/77), respectively. The expression of PD-L1 in OC cells was significantly correlated with FIGO stage (P=0.026), while its expression was not significantly correlated with other clinicopathological parameters. There was no significant correlation between PD-L2 and any clinicopathological parameters. Kaplan-Meier survival analysis showed that the OS of high PD-L1 expression group was significantly shorter compared with the low PD-L1 expression group (HR =2.689, 95% CI: 1.400-5.163). Patients with high PD-L2 expression also exhibited significantly shorter OS (HR =2.204, 95% CI: 1.037-4.682). Multivariable analysis displayed that high expression of PD-L1 (HR =2.275, 95% CI: 1.120-4.169), high expression of PD-L2 (HR =2.314, 95% CI: 1.136-4.714) and FIGO stage (HR =11.229, 95% CI: 1.373-91.865) were independent prognostic factors of OC. When negative expressions of both PD-L1 and PD-L2 were used as a combined prognostic factor, the OS was significantly prolonged (HR =3.396, 95% CI: 1.858-6.029). According to our previous studies, patients with negative PD-L1 expression and high T-bet

conclusionsCo-stimulatory molecules, PD-L1 and PD-L2, were highly expressed in OC tissues, and their expression levels were correlated with FIGO stage, age and prognosis. These results suggested that PD-L1 and PD-L2 were involved in the occurrence and development of malignant OC, indicating their potential value in clinical diagnosis and prognosis of OC.

Indexed as

Co-stimulatory moleculeovarian cancer (OC)programmed death ligand-1 (PD-L1)programmed death ligand-2 (PD-L2)T-bet

Identifiers

PMID35116740
PMCPMC8797717
OpenAlexW4238380760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.